SML2807
JP4-039
≥98% (HPLC)
别名:
4-[[(3E,5S)-5-[[(1,1-Dimethylethoxy)carbonyl]amino]-7-methyl-1-oxo-3-octen-1-yl]amino]-2,2,6,6-tetramethyl-1-piperidinyloxy, JP 4-039
InChI
1S/C23H42N3O4/c1-16(2)13-17(25-20(28)30-21(3,4)5)11-10-12-19(27)24-18-14-22(6,7)26(29)23(8,9)15-18/h10-11,16-18H,12-15H2,1-9H3,(H,24,27)(H,25,28)/b11-10+/t17-/m1/s1
InChI key
AJHRJWQXDNEJAG-SXSDINLZSA-N
SMILES string
O=C(C/C=C/[C@@H](NC(OC(C)(C)C)=O)CC(C)C)NC1CC(C)(C)N([O])C(C)(C)C1
assay
≥98% (HPLC)
form
powder
color
faint yellow to dark orange
solubility
DMSO: 2 mg/mL, clear
storage temp.
−20°C
Quality Level
Biochem/physiol Actions
JP4-039 is an electron-/reactive oxygen species (ROS)-scavenging GS-nitroxide composed of 4-amino-TEMPO and a truncated gramicidin S (GS) mitochrondria-targeting sequence. JP4-039 is a superior irradiation mitigator than XJB-5-131 (33% vs. 20% mice survial rate on day 35 with respective compound; 23.6 μmol/kg iv. 24 hr post 9.5 Gy whole body irradiation), while displaying weaker anti-ferroptotic potency (EC50 = 3.58 μM/1.27 μM against 10 μM erastin-/2 μM RSL3-induced HT-1080 ferroptosis vs. 114 nM/68 nM with XJB-5-131) due to lower lipophilicity & mitochondria enrichment. Typical dosing range: 40 nM-10 μM in cultures and 10-20 mg/kg in mice (im., ip., iv.) in vivo.
Mitochondrial-targeted reactive oxygen species (ROS)-scavenging gramicidin S (GS)-nitroxide with in vitro and in vivo efficacy against irradiation-induced damage.
存储类别
11 - Combustible Solids
wgk
WGK 3
Mark E Bernard et al.
Radiation research, 176(5), 603-612 (2011-09-24)
Fanconi anemia (FA) is an inherited disorder characterized by defective DNA repair and cellular sensitivity to DNA crosslinking agents. Clinically, FA is associated with high risk for marrow failure, leukemia and head and neck squamous cell carcinoma (HNSCC). Radiosensitivity in
Liang Wei et al.
Scientific reports, 8(1), 2072-2072 (2018-02-03)
Total body irradiation (TBI) leads to dose- and tissue-specific lethality. In the current study, we demonstrate that a mitochondrion-targeted nitroxide JP4-039 given once 24 hours after 9-10 Gy TBI significantly improves mouse survival, and the recovery of intestinal barrier, differentiation and stem
Michael W Epperly et al.
In vivo (Athens, Greece), 32(5), 1009-1023 (2018-08-29)
The mitochondrial targeted GS-nitroxide, JP4-039, is an effective total body irradiation (TBI) mitigator when delivered intravenously (IV) up to 72 h after exposure. Effective systemic and localized administration to oral cavity/oropharynx and esophagus has been demonstrated. The objective of the
Michael W Epperly et al.
In vivo (Athens, Greece), 24(6), 811-819 (2010-12-18)
this study evaluated esophageal radioprotection by the Gramicidin S (GS) derived-nitroxide, JP4-039, a mitochondrial targeting peptide-isostere covalently-linked to 4-amino-Tempo, delivered in a novel swallowed oil-based (F15) formulation. C57BL/6HNsd female mice received intraesophageal F15 formulation containing JP4-039 (4 mg/ml in 100
Julie P Goff et al.
In vivo (Athens, Greece), 25(3), 315-323 (2011-05-18)
Total-body irradiation (TBI) doses in the range of 2-8 Gy are associated with a drop in peripheral blood counts, decreased bone marrow cellularity, and hematopoietic syndrome. Radiation mitigators must be safe for individuals likely to recover spontaneously. Female C57BL/6HNsd mice
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持